Back to News
Market Impact: 0.3
ALK-Abelló's ACARIZAX Meets Phase 3 Goal, Supports Planned China Filing
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
ALK-Abelló reported positive topline results from a Phase 3 trial evaluating ACARIZAX, its house dust mite sublingual immunotherapy tablet, in Chinese patients. The available article text provides no numerical efficacy results or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ALK.B0.70
More News
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India
- Credit stress is threatening to unwind the AI bull. All eyes are on Oracle to hold the line
- LightStream stops accepting loan applications. Try these 6 lenders instead
- Ciena EVP DiPerna sells $308,865 in CIEN stock